TY - JOUR
T1 - Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP)
T2 - a retrospective analysis from an early access program
AU - Illini, Oliver
AU - Fabikan, Hannah
AU - Swalduz, Aurélie
AU - Vikström, Anders
AU - Krenbek, Dagmar
AU - Schumacher, Michael
AU - Dudnik, Elizabeth
AU - Studnicka, Michael
AU - Öhman, Ronny
AU - Wurm, Robert
AU - Wannesson, Luciano
AU - Peled, Nir
AU - Kian, Waleed
AU - Bar, Jair
AU - Daher, Sameh
AU - Addeo, Alfredo
AU - Rotem, Ofer
AU - Pall, Georg
AU - Zer, Alona
AU - Saad, Akram
AU - Cufer, Tanja
AU - Sorotsky, Hadas Gantz
AU - Hashemi, Sayed M.S.
AU - Mohorcic, Katja
AU - Stoff, Ronen
AU - Rovitsky, Yulia
AU - Keren-Rosenberg, Shoshana
AU - Winder, Thomas
AU - Weinlinger, Christoph
AU - Valipour, Arschang
AU - Hochmair, Maximilian J.
N1 - Publisher Copyright:
© The Author(s), 2022.
PY - 2022/1/1
Y1 - 2022/1/1
N2 - Background: Patients with non-small cell lung cancer (NSCLC) presenting with mesenchymal–epithelial transition (MET) exon 14 skipping mutation have an unfavorable prognosis with standard treatments. Capmatinib is a selective MET inhibitor, which showed promising efficacy in this patient population in early trials. Methods: We performed a retrospective, international, multicenter efficacy and safety analysis in patients with NSCLC treated with capmatinib in an early access program between March 2019 and December 2021. Results: Data from 81 patients with advanced MET exon 14 mutated NSCLC treated with capmatinib in first- or later-line therapy were analyzed. Median age was 77 years (range, 48–91), 56% were women, 86% had stage IV disease, and 27% had brain metastases. For all patients, the objective response rate (ORR) to capmatinib was 58% (95% CI, 47–69), whereas it was 68% (95% CI, 50–82) in treatment-naïve and 50% (95% CI, 35–65) in pretreated patients. The median progression-free survival was 9.5 months (95% CI, 4.7–14.3), whereas it was 10.6 months (95% CI, 5.5–15.7) in first-line and 9.1 months (95% CI, 3.1–15.1) in pretreated patients. After a median follow-up of 11.0 months, the median overall survival was 18.2 months (95% CI, 13.2–23.1). In patients with measurable brain metastases (n = 11), the intracranial ORR was 46% (95% CI, 17–77). Capmatinib showed a manageable safety profile. Grade ⩾ 3 treatment-related adverse events included peripheral edema (13%), elevated creatinine (4%), and elevated liver enzymes (3%). Conclusion: In patients with MET exon 14 skipping mutation, capmatinib showed durable systemic and intracranial efficacy and a manageable safety profile. This analysis confirms previously reported phase II data in a real-world setting.
AB - Background: Patients with non-small cell lung cancer (NSCLC) presenting with mesenchymal–epithelial transition (MET) exon 14 skipping mutation have an unfavorable prognosis with standard treatments. Capmatinib is a selective MET inhibitor, which showed promising efficacy in this patient population in early trials. Methods: We performed a retrospective, international, multicenter efficacy and safety analysis in patients with NSCLC treated with capmatinib in an early access program between March 2019 and December 2021. Results: Data from 81 patients with advanced MET exon 14 mutated NSCLC treated with capmatinib in first- or later-line therapy were analyzed. Median age was 77 years (range, 48–91), 56% were women, 86% had stage IV disease, and 27% had brain metastases. For all patients, the objective response rate (ORR) to capmatinib was 58% (95% CI, 47–69), whereas it was 68% (95% CI, 50–82) in treatment-naïve and 50% (95% CI, 35–65) in pretreated patients. The median progression-free survival was 9.5 months (95% CI, 4.7–14.3), whereas it was 10.6 months (95% CI, 5.5–15.7) in first-line and 9.1 months (95% CI, 3.1–15.1) in pretreated patients. After a median follow-up of 11.0 months, the median overall survival was 18.2 months (95% CI, 13.2–23.1). In patients with measurable brain metastases (n = 11), the intracranial ORR was 46% (95% CI, 17–77). Capmatinib showed a manageable safety profile. Grade ⩾ 3 treatment-related adverse events included peripheral edema (13%), elevated creatinine (4%), and elevated liver enzymes (3%). Conclusion: In patients with MET exon 14 skipping mutation, capmatinib showed durable systemic and intracranial efficacy and a manageable safety profile. This analysis confirms previously reported phase II data in a real-world setting.
KW - capmatinib
KW - lung cancer
KW - MET exon 14 skipping mutation
KW - NSCLC
KW - targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=85132312063&partnerID=8YFLogxK
U2 - 10.1177/17588359221103206
DO - 10.1177/17588359221103206
M3 - Article
AN - SCOPUS:85132312063
SN - 1758-8340
VL - 14
JO - Therapeutic Advances in Medical Oncology
JF - Therapeutic Advances in Medical Oncology
ER -